By Kalaria, Ashok J.; Kumar, Mukesh; Sidhdhpura, Ankur A.; Chauhan, Yogendra
The present invention relates to a novel process for the prepn. of 1-phenyl-3- aminopropane deriv. compds. corresponding to the formula (I) and/or its intermediates, and/or its stereo specific isomers or pharmaceutically acceptable salts, hydrates, or solvates thereof.
Process for preparing tapentadol by Wittig reaction, useful for treating pain. Also claims novel intermediates of tapentadol such as and their preparation. Represents the first patenting to be seen from Unimark that focuses on tapentadol – it having been developed and launched by Grunenthal and its licensee J&J.
In May Newport Premium™ reported that Unimark was potentially interested in tapentadol. Family members of the product case, EP693475, hold SPC protection in the EU until 2020 and one of its Orange Book listed filings (US39593) expire in US in 2022. In May 2015, the US FDA's Orange Book was seen to list patent describing crystalline form of tapentadol/Nucynta (US7994364) that was due to expire in June 2025
A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
Unimark Remedies Limited
|TAKE A TOUR